naviHealth’s Post

Introducing David Alexander Dickie as part of our monthly employee spotlight #WeAreOptumUK. Not many people know that we have a Data Science Unit, other-wise known as the DSU by folks at Optum. The team that work in the DSU will truly blow your mind with their innovative ideas and solutions. Leading up that team in the UK is Dr. David Dickie. If you haven't had the pleasure of meeting David face to face or on a Teams meeting then you are missing out. He brings a certain sparkle✨ to Optum and most recently a very valued team member of the Medicines Optimisation team, where he worked with us on bringing the data to life on our work on antibiotic stewardship. So, without further ado, let's see what David has to say about his time working at Optum: 👉🏼 How long have you worked at Optum? 🧡 2.916 years. 👉🏼 That's very specific David (lol), and what was your professional background before joining Optum? 🧡 I was a neuroscientist. 👉🏼 That sounds interesting.... and what do you do now at Optum? 🧡 I lead the Optum UK Data Science Unit (DSU) that is developing artificial intelligence tools to make the healthcare system work better for everyone. 👉🏼 What do you enjoy most about that? 🧡 SCIENCE and working with EXTREMELY smart people. 👉🏼 And you proudest achievement at Optum? 🧡 Establishing a team of world class data scientists and watching them produce world class solutions to improve people’s lives! 🔊 Big shout out to Dr. David Dickie if you know him, worked with him or just because you think he's awesome. I'd love to hear some of your stories. #healthcare #kudos #GetToKnowTheTeam

On the seventh day of Querymas, Optum reduced their costs! The Optum team achieved 10X faster queries and a 30% reduction in infrastructure costs in collaboration with Starburst, leading to an estimated savings of $8 million. Read the full story here:https://okt.to/RXDjbk #CustomerStories #casestudy #12DaysofQuerymas

🆕 📽 📖 Explore the forefront of healthcare innovation on the latest episode of the HFS Research Fireside Chat! Our CEO & Chief Analyst, Phil Fersht talks with Sandeep Dadlani, Executive VP, Chief Digital & Technology Officer at UnitedHealth Group. • Discover the transformative power of GenAI and its profound impact on the healthcare industry.  • Gain insights into how GenAI is reshaping our approach to healthcare services. • Delve into thought-provoking questions such as: o How is GenAI revolutionizing the healthcare landscape? o What implications does GenAI hold for the future of healthcare services? o Will GenAI serve as a catalyst for progress, or will it fundamentally alter the way we acquire and consume healthcare services? 📺 This is a conversation you won't want to miss: https://lnkd.in/g3panyrq 📑 Read the associated blog, “Be pragmatic, excited, and responsible: how to get GenAI done” here: https://lnkd.in/gC4en8vw Saurabh Gupta, Emma Melando, Rohan Kulkarni, Sia Rostami Ravari, David Cushman, Dana Daher, Pete Simpkinson, Monique Burruss, HFS Research, UnitedHealth Group #Healthcareinnovation #GenAI #ResponsibleAI #Healthcare #HealthcareIndustry #Technologyshift

ALL ABOARD THE DATA EXPRESS The train has left the station but is patient relevant data left on the platform? Pharma companies have been building #patientexperience platforms that harvest data for over a decade. There are some fantastic platforms out there — kudos to @Teva for example who created ‘MyDay’ for people living with cancer and also ‘Life Effects’ which is condition-agnostic and encourages patients to share hacks and tips about living with conditions. Both of these were the brainchild of the fabulous Ruth Wilson who is one of our most highly respected members at #ISPEP. That’s pharma. What about the #PatientAdvocacy groups. These organizations now match pharma in the platforms they create and when it comes to generating data of the greatest relevance to patients they are evolving the insights model. Here’s where kudos goes to platforms like ‘Inspire’ created by Brian Loew to link patients with clinical trials. Second generation platforms like ‘People With…’ (Mark Bradley) inspire me and I’m fascinated by the work of the team at ‘A Life In A Day’ (Mark Doyle) who are capturing the patient experience of trial participation in a highly creative way. Regulators have caught up with this and are inviting data beyond PROMs and PREMs — they welcome caregiver data, observer data and family data. Importantly, they are starting to listen to the real world experience of patients beyond the clinical trials model. The collaboration between regulators and patients is changing to keep up with these data from the patient platforms. However pharma is still overlooking the value of #patientgenerated data. That’s data from a patient platform, a patient app, a patient survey that should be included in a company’s evidence generation plans. It’s still primarily about evidence for HCPs with patient data an afterthought. Why? I think it’s all about inertia — the classic pantomime villain in a Biopharma. Inertia comprises two things — fear and mistrust. In practical terms, this presents as downsizing the importance of patient-generated data. If the data isn’t generated by the company, they consider it ‘dirty data’. The business folks don’t trust it. The compliance folks fear it. So it’s closed down as a ‘risk’. Then they don’t have to deal with it. The irony is, all they have to do is collaborate with patient orgs and ‘clean it up’ to clinical standards. The same data is relevant in different ways to all stakeholders. At #ISPEP we will use our collective experience to figure these kinds of challenges out. Because the data train will keep chugging forward and clinical evidence must include patient data too. After all; nothing about us without us is the founding principle of Patient Focussed Medicine Development #PatientEngagement #PatientCentricity #PatientEngagementProfessionals #PatientsFirst #PFDD #PFMD #PatientExperience #PatientVoice #PatientInsights #PatientData #RWD

Today at 2 PM I'm attending the first virtual session for 2024 of HealthIMPACT Live virtual. At 3:50 PM ET the latest episode of "5 Good Things" with Megan Antonelli will air. I am thrilled to share good things- here are SOME (but not all) of the things I am going to talk about. 1. I shared some of the news that Erin Brodwin from Axios reported about Rune Labs and their Parkinson's development. https://lnkd.in/d3puu2DD First of all she's a great reporter and I'm secretly planning to invite her to interview people with HealthIMPACT Live (you heard it here first). Secondly one of my grandfathers died of Parkinson's and I'm thrilled that there are people working to improve things. 2. CMS has a chief competition officer. Stacy Sanders has been appointed to work on lowering healthcare and prescription drug costs and coordination with the FTC and DOJ to discuss anticompetitive healthcare technology data practices. I would love to discuss that more- I've seen companies with questionable data ethics about AI development for healthcare- and I think if you are appointed to do this work you must be a MASTER of balance. BONUS I got to talk about the Sharp Index awards for this year. A series on hope, we want to make it super popular to work to help others! Technology companies you are needed! Physicians, you are needed. Everyone is needed. learn about the awards here: https://lnkd.in/d2gBtWw8 #SharpIndexAwards Register for free: https://lnkd.in/gmVwV4SV Follow the hashtag #HealthIMPACT

The linkage of clinical trial data to real world data is gaining momentum across the industry, and is actively being used by sponsors of varying size and therapeutic focus to provide insight into the longitudinal patient journey. I'm excited to take the stage at @Medidata-Solutions NEXT Boston on May 21 to discuss how Medidata Link accelerates access to innovative treatments while minimizing burden for sponsors, sites and patients alike. #MedidataNEXT #RealWorldData #Medidata

Way too early take on the IQVIA "one home" annoucement: It probably will win? I'm not a technologist but it seems like eveyone agrees in concept: we're only going to have MORE tech not less moving forward AND it's already burdensome and out of hand. Most of the people I've heard speak at length think that a vertically integrated single solution is either unlikely or impossible which leaves this sort of universal adapter for tech as the best alternative. If it works. And gets adoption. Being one of the biggest CROs with a great pedigree will give IQVIA a head start in category two, which just leaves the functionality piece up in the air. We're probably not seeing a press release if they're not already confident in the platform's ability to deliver though. I do sort of wish the industry had taken a zelle-like approach though. Did you know that Zelle's parent company Early Warning Services, LLC is actually co-owned by the seven largest banks in the US? This collaborative approach means Zelle covers > 80% of Americans, allowing these stalwart institutions to stay relevant in the rapidly evolving digital payments space. It ALSO allows them to offer certain services for free that other payment platforms like Venmo charge for. If "One Home" is truly aiming to be THE tech-bridging solution, they'll have to convince other CROs to bend the knee - otherwise they can expect a tech knife fight which might lead us right back to where we started: a bunch of CROs all have their own tech-neutral platform that can connect everything - BUT SITES STILL HAVE TO LOG IN TO 7 DIFFERENT ONES. Am I way off?

Steve Wimmer’s insights on the Zelle model are a fresh look & completely transferable to our industry. If you’re into sharp takes, give him a follow for regular #WimmerWit. Back on topic - if we were actually site-centric or patient-focused that Zelle model would work. But since we’re profit focused, it would take a Mike Bloomberg entrepreneurial agnostic fully-funded approach to making clinical research operational seamlessness happen… But who’s that? So, for now, IQVIA’s “One Home for Sites” is out of the gate the forerunner. Regarding a couple of comments I’ve seen, I’ll remind folks that - much more than a CRO - IQVIA IS a tech company. They were forged by the merger of Quintiles (CRO) & IMS (Tech) - they’ve been building their own proprietary tech & and have acquired >300 companies since their inception - many or most being smaller tech companies. However, there’s at least one other who has silently been building behind the scenes yet with full transparency - and I see a number of features that give these competitive advantage. Stay tuned… #techtalk #sitecentricity #patientpriority #sponsorsupport #biotechbooster #vendorvelocity #CROsavvy #cuttingedgeconsults #InvestorInsights #stakeholderstrategies #forerunners #darkhorse #DontSayIDidntTellYou The press release we’re referencing: https://lnkd.in/e7bzAjsb

Ranging from appropriate patient targeting to precisely locating patients that are experiencing gains, real-world evidence can realize various benefits for life sciences companies. Infosys dives into the prominence of real-world data, its value for various stakeholders in the industry, and its analytical use cases. Learn more: https://infy.com/3L5hW9l #InfyLifeSciences #BreakthroughsForLife #LifeSciences #Data

My dear trial-matching-companies- (and anyone who still likes to believe that the issues with trial recruitment lie in the *matching* 🙄 ) Lately, we in MPNEurope have been getting some more of that again and as #Melanoma community, we *know* what it is like to rely on clinical trials to survive, so here some pointers to keep future exchanges constructive. 1. if your life is at stake, the last thing you want to be is on a clinical trial. In the best scenario, trials cost time (that you'd rather spend with your family) and money (that you might not have). In the worst, you end up on treatment that you don't want (and still invest time and money for THAT) and additional invasive treatments. Besides, you want something that *works*. 2. You'll obviously say you care about Science and all that- but honestly- that pay-walled publication and ESMO/ ASCO presentation- you're likely going to be dead by that time anyway- but as your onc cares, you obviously say yes (can't afford to upset the person you depend on for your care) but if you REALLY talk to people- people care about seeing their kids grow up, about growing old with the love of their lives. Not about someone else's papers. 3. Rubbish in, rubbish out. Shiny user-friendly mask aside...you still pull your data from clinicaltrials.gov.... 4. Your business model matters. You want my grandmother's shoe size to even search for a some (clinicaltrials.gov pulled) trial- you are just profiling people (to sell the data no less). How much do you get per trial referral and how does that affect the ranking of your trial propositions? Honestly, we don't need yet another pseudo-patient-friendly surface pulling data from https://lnkd.in/gtBd23MH with some dodgy underlying business model with some lofty claims to scientific relevance and it can have AI thrown into it 200 times over. What we WOULD need were services that would tell a patient 'this trial due to the drug (REF REF REF) and its design (no blinding, on randomisation to dodgy stuff, no other crop-outs) will increase your chances of survival by y' and we don't make money on just profiling you and our search algorithms aren't influenced by commissions or other non-scientific tweakery'. Now THAT would be worth talking about.